Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Tables)

v3.21.2
Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2021
Discontinued Operations  
Schedule of components of loss from discontinued operations as reported in our statements of operations and comprehensive loss and assets and liabilities reported as discontinued operations in our condensed balance sheets

    

Three Months Ended

Nine Months Ended

September 30, 2020

September 30, 2020

 

(In thousands, except per share data)

Revenue:

 

  

Product revenue

$

102

$

388

Costs and expenses:

 

  

 

Cost of goods sold

 

683

 

1,082

Research and development

 

675

 

1,503

Selling, general and administrative

 

2,221

 

6,084

Total costs and expenses

 

3,579

 

8,669

Loss from discontinued operations

 

(3,477)

 

(8,281)

Other expense, net

 

 

Net loss from discontinued operations

$

(3,477)

$

(8,281)

Basic and diluted net loss per common share from discontinued operations

$

(1.07)

$

(2.70)

Weighted average shares used in computing basic and diluted net loss per common share

 

3,264

 

3,062

September 30, 

    

December 31,

    

2021

    

2020

(In thousands)

  

 

  

Receivables

$

160

$

Prepaid expenses and other current assets

27

181

Discontinued operations – current assets

$

187

$

181

Accounts payable

$

752

$

1,515

Accrued clinical trials expenses

 

9

 

80

Accrued sales allowances

 

 

61

Other accrued liabilities

 

352

 

304

Discontinued operations – current liabilities

$

1,113

$

1,960